The FDA announced it would no longer require clinical trials of “Gender Affirming” therapies for children. Assistant Secretary for Health, Rachel Lavine stated, “we are in a crisis and children need these life saving drugs sooner rather than later.” The FDA’s Deputy Commissioner for policy, legislation, and International Affairs Andi Lipstein Fristedt explained the reasoning behind the decision. “The very concept of medical standards such as clinical trials and longitudinal studies are relics of western power structures that are in place solely to ensure the ongoing systemic exclusion of marginalized ideology.”
Endo Pharmaceuticals immediately responded with the release of their new chemical castration drug Nonadzitol and it’s gender opposite Addadiktomy.